Cell-surface marker expression by human BM ALDHlo- and ALDHhi-derived CFC in Amniomax or complete EGM-2 media
| Cell type . | Hematopoietic . | Progenitor . | Endothelial . | Endothelial/mesenchymal . | |||||
|---|---|---|---|---|---|---|---|---|---|
| CD45 (%) . | CD14 (%) . | CD34 (%) . | CD133 (%) . | CD31 (%) . | CD144 (%) . | CD105 (%) . | CD73 (%) . | CD90 (%) . | |
| ALDHlo MCFC | 0.3 ± 0.1 | 0.2 ± 0.1 | 0.2 ± 0.1 | 0.3 ± 0.1 | 0.4 ± 0.2 | 0.6 ± 0.4 | 98.4 ± 0.9 | 99.5 ± 0.4 | 97.8 ± 1.8 |
| ALDHhi MCFC | 0.2 ± 0.1 | 0.4 ± 0.1 | 0.3 ± 0.1 | 0.8 ± 0.5 | 0.4 ± 0.1 | 0.4 ± 0.2 | 98.6 ± 0.8 | 99.8 ± 0.1 | 98.3 ± 0.5 |
| ALDHhi in EGM-2 | 0.5 ± 0.2 | 0.7 ± 0.1 | 0.3 ± 0.1 | 0.6 ± 0.1 | 0.7 ± 0.2† | 0.9 ± 0.6† | 81.7 ± 4.6 | 99.9 ± 0.1 | 38.5 ± 9.3* |
| HAEC in EGM-2 | 0.3 ± 0.1 | 0.4 ± 0.1 | 5.8 ± 4.6 | 0.6 ± 0.1 | 98.9 ± 1.0 | 50.0 ± 6.2 | 99.4 ± 0.2 | 99.0 ± 0.8 | 0.9 ± 0.3 |
| Cell type . | Hematopoietic . | Progenitor . | Endothelial . | Endothelial/mesenchymal . | |||||
|---|---|---|---|---|---|---|---|---|---|
| CD45 (%) . | CD14 (%) . | CD34 (%) . | CD133 (%) . | CD31 (%) . | CD144 (%) . | CD105 (%) . | CD73 (%) . | CD90 (%) . | |
| ALDHlo MCFC | 0.3 ± 0.1 | 0.2 ± 0.1 | 0.2 ± 0.1 | 0.3 ± 0.1 | 0.4 ± 0.2 | 0.6 ± 0.4 | 98.4 ± 0.9 | 99.5 ± 0.4 | 97.8 ± 1.8 |
| ALDHhi MCFC | 0.2 ± 0.1 | 0.4 ± 0.1 | 0.3 ± 0.1 | 0.8 ± 0.5 | 0.4 ± 0.1 | 0.4 ± 0.2 | 98.6 ± 0.8 | 99.8 ± 0.1 | 98.3 ± 0.5 |
| ALDHhi in EGM-2 | 0.5 ± 0.2 | 0.7 ± 0.1 | 0.3 ± 0.1 | 0.6 ± 0.1 | 0.7 ± 0.2† | 0.9 ± 0.6† | 81.7 ± 4.6 | 99.9 ± 0.1 | 38.5 ± 9.3* |
| HAEC in EGM-2 | 0.3 ± 0.1 | 0.4 ± 0.1 | 5.8 ± 4.6 | 0.6 ± 0.1 | 98.9 ± 1.0 | 50.0 ± 6.2 | 99.4 ± 0.2 | 99.0 ± 0.8 | 0.9 ± 0.3 |
Human BM ALDHlo- and ALDHhi-derived cells established plastic adherent colonies in Amniomax media, composed of stromal fibroblast cells that expressed CD105, CD73, and CD90. ALDHhi cells established proliferative nonhematopoietic colonies in EGM-2 media, and were composed of cells that did not express the EC markers CD31 or CD144, and demonstrated intermediate expression of the stromal fibroblast marker CD90. All cell-surface markers were assessed by FACS.
P < .05 compared with HAEC, n = 3-4.
P < .01 compared with HAEC, n = 3-4.